Design, synthesis and biological evaluation of pyrimidine derivatives as novel CDK2 inhibitors that induce apoptosis and cell cycle arrest in breast cancer cells
作者:Yiting Wang、Yanmei Chen、Xiaoling Cheng、Ke Zhang、Hangyu Wang、Bo Liu、Jinhui Wang
DOI:10.1016/j.bmc.2018.05.024
日期:2018.7
that the compound 25 is a potent CDK2 inhibitor exhibiting a broad spectrum anti-proliferative activity against several human breast cancer cells. Additionally, compound 25 could block cell cycle at G0 or G1 and induce significant apoptosis in MDA-MB-468 cells. These findings highlight a rationale for further development of CDK2 inhibitors to treat human breast cancer.
细胞周期蛋白依赖性激酶2(CDK2)在真核细胞周期进程中起关键作用,这可能有助于从G1到S期的过渡。CDK2的失调与许多癌症密切相关。CDK2被用作肿瘤学中研究最多的激酶靶标之一。在本文中,设计,合成和研究了24种苯甲酰胺衍生物对CDK2的抑制活性。我们的结果表明,化合物25是一种有效的CDK2抑制剂,对几种人乳腺癌细胞表现出广谱的抗增殖活性。此外,化合物25可以阻断G0或G1的细胞周期,并诱导MDA-MB-468细胞显着的凋亡。这些发现突出了进一步开发CDK2抑制剂来治疗人类乳腺癌的基本原理。